208 related articles for article (PubMed ID: 37342332)
21. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
22. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
23. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
[TBL] [Abstract][Full Text] [Related]
27. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
[TBL] [Abstract][Full Text] [Related]
28. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
30. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
32. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
33. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
35. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
39. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
40. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
